Effects of Sulforaphane Supplementation on Athletic Perfo... | NCT07343518

Studies
Effects of Sulforaphane Supplementation on Athletic Performance

NCT07343518

Sponsor

University of Maia

Status

Not yet recruiting

Last Update Posted

Jan 15, 2026Actual

Enrollment

20Estimated

Phase

Not Applicable

Conditions

Nutrition
Sports

Interventions

Fatigue protocol

Countries

Not provided

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Jan 2026

Overall Recruitment Status or Expanded Access Status

Not yet recruiting

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Jan 2, 2026Estimated

Primary Completion Date

Apr 1, 2026Estimated

Completion Date

May 1, 2026Estimated

First Submitted Date

Dec 20, 2025

First Submission Date that Met QC Criteria

Jan 6, 2026

First Posted Date

Jan 15, 2026Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Jan 6, 2026

Last Update Posted Date

Jan 15, 2026Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

Considering the promising effects observed and the scarce and incipient scientific background of SFN in sports, the present study aims to evaluate the effects of SFN supplementation on fatigue, EIMD and recovery in trained individuals. In particular, outcomes such as time to exhaustion (TTE), and perceptual questionnaires of muscle soreness, recovery, and fatigue will be assessed, aiming to explore the effectiveness of SFN.

Detailed Description

Not provided

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Not Applicable

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

20Estimated

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Sulforaphane	Experimental	Sulforaphane supplementation (Nomio)	Other: Fatigue protocol
Placebo	Placebo Comparator	Placebo intervention	Other: Fatigue protocol

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Fatigue protocol	Other	Fatigue protocol comprising 6 sets of 30 seconds at 120% of velocity of maximal oxygen consumption	Placebo Sulforaphane

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
time to exhaustion		24 hours

Secondary Outcomes

Measure	Description	Time Frame
Rating of Fatigue Scale		Baseline, 30 minutes, 24 hours
Total Quality Recovery Scale		Baseline, 30 minutes, 24 hours
Muscle soreness (Visual analogue scale)

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Physically active individuals (engaging in exercise 3 or more times per week)

Exclusion Criteria:

Individuals that experience musculoskeletal injuries or have experienced in the past 3 months

Accepts Healthy Volunteers

Yes

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

35 Years

Standard Ages

Adult

Study Population

Not provided

Sampling Method

Not provided

IPD Sharing Statement Module

Plan to Share IPD

Undecided

Description

Not provided

Types

Not provided

Time Frame

Not provided

Access Criteria

Not provided

URL

Not provided

Condition Browse Module

MeSH Terms

ID	Term
D005221	Fatigue

Ancestor Terms

ID	Term
D012816	Signs and Symptoms
D013568	Pathological Conditions, Signs and Symptoms

Browse Leaves

Not provided

Browse Branches

Not provided

Masking Info

Masking

Double

Masking Description

Both participants and investigator will be blinded to the experimental conditions. Both placebo and supplementation will have the same appearence. Only the outcome assessor will know the assigned sequence to each participant

Who Masked

ParticipantInvestigator